LLY

T13.5% portfolio

Eli Lilly and Company

Next est. report 2026-10-29 · BMO

Archetypes '26: Optimizers Biotech '26: AI Driven Drug Discovery GLP-1 Long '24: GLP1 Drug Producer

Loading…

Loading chart…

Overview

Eli Lilly and Company discovers, develops, and sells human medicines globally, primarily in cardiometabolic health, oncology, immunology, and neuroscience. Thei

Eli Lilly and Company discovers, develops, and sells human medicines globally, primarily in cardiometabolic health, oncology, immunology, and neuroscience. Their incretin drugs like Mounjaro and Zepbound are major revenue drivers, with strong growth across other therapeutic areas. They sell to healthcare providers, patients, wholesalers, PBMs, and government entities, with growing direct-to-consumer sales via LillyDirect and expanded Medicare access.

Key Inputs And Sourcing

1. Active Pharmaceutical Ingredients (APIs)

component · Global, with increasing US production (Lebanon, Indiana) for GLP-1s · 5-10%

Source Core component of all pharmaceutical products; Lilly is building the largest US API plant for metabolic medicines, expected to open in 2027.

Confidence: high

2. Autoinjector Components

component · Global (specialized manufacturers) · unknown

Source Explicitly identified as a potential supply chain constraint due to GLP-1 demand. [cite: Theme_BullBearDetails, 21] Components include plastics, springs, glass vials, and needles.

Confidence: high

3. Biologics Manufacturing Inputs (e.g., Cell Culture Media)

component · Global · unknown

Source Critical for the production of complex biological drugs like GLP-1s; cell culture media is a major source of variability.

Confidence: high

4. Excipients

component · Global · unknown

Source Essential inactive ingredients for drug formulation and stability.

Confidence: medium

5. Skilled Labor (Manufacturing)

labor · US (Indiana, North Carolina), Ireland, Netherlands, India · unknown

Source Significant hiring for new and expanded manufacturing facilities across multiple geographies.

Confidence: high

6. Packaging Materials (excluding autoinjectors)

packaging · Global · unknown

Source Standard pharmaceutical packaging components such as vials, bottles, cartons, and labels.

Confidence: medium

7. Energy (Electricity, Natural Gas)

energy · Local to manufacturing sites (US, Ireland, Netherlands, India) · unknown

Source Required to power manufacturing facilities and processes.

Confidence: medium

8. Logistics & Distribution

logistics · Global · unknown

Source Encompasses the transportation of raw materials to manufacturing sites and finished products to markets worldwide.

Confidence: high

9. Water (for Injection/Process)

commodity · Local to manufacturing sites · unknown

Source Critical utility for pharmaceutical processes, including purification and cleaning.

Confidence: low

Industry Publications

Fierce Pharma (fiercepharma.com) — Comprehensive coverage of pharmaceutical industry news, including manufacturing, marketing, finance, and regulatory developments relevant to Lilly's commercial operations and supply chain.
Endpoints News (endpointsnews.com) — Provides sharp analysis and insider reporting on biotech and pharma, covering business deals, M&A, FDA actions, and clinical data, crucial for monitoring Lilly's pipeline and strategic acquisitions.
STAT News (statnews.com) — Focuses on the convergence of science, policy, and journalism in healthcare, offering insights into regulatory changes, scientific breakthroughs, and public health issues impacting Lilly's R&D and market access.
BioPharma Dive (biopharmadive.com) — Offers quick, digestible, and reliable updates for pharmaceutical executives, with strong coverage of GLP-1 market dynamics, clinical trials, and competitive landscape.
Pharmaceutical Executive (pharmexec.com) — Covers business strategy, leadership, and market trends within the pharmaceutical industry, including company rankings, dealmaking, and policy pressures, highly relevant for Lilly's strategic direction and market position.

Economic Data Watch

1. FRED (Federal Reserve Economic Data) — Personal Consumption Expenditures

Metric/field PCEHC (Personal Consumption Expenditures: Health Care)

Cadence monthly

Why it matters Directly reflects the overall spending by individuals on healthcare services and products, indicating the size and growth of the market LLY operates in.

Signal to watch Sustained upward trend indicates a growing market for LLY's products.

Confidence: high

2. FRED (Federal Reserve Economic Data) — Income & Spending

Metric/field DPIC96 (Real Disposable Personal Income)

Cadence monthly

Why it matters A significant portion of LLY's obesity drug sales (e.g., Zepbound) are self-pay. Higher disposable income supports consumer's ability to afford these treatments.

Signal to watch Growth in real disposable income suggests increased consumer purchasing power for self-pay treatments.

Confidence: high

3. FRED (Federal Reserve Economic Data) / BLS — Consumer Price Index

Metric/field CPIAPP (Consumer Price Index for All Urban Consumers: Medical Care)

Cadence monthly

Why it matters Indicates the general trend of medical inflation, impacting pricing discussions with payers and the affordability for patients, especially relevant given LLY's 'volume-over-price' strategy and expected price declines.

Signal to watch Lower or stable growth in medical care CPI could ease pricing pressures.

Confidence: medium

4. International Monetary Fund (IMF) — World Economic Outlook (WEO) Database

Metric/field Gross domestic product, constant prices, percent change (for key international markets)

Cadence quarterly/annually

Why it matters LLY has significant and growing international revenue (Europe, Japan, China, Rest of World). Global economic health directly impacts demand and reimbursement capabilities in these markets.

Signal to watch Upward revisions or sustained growth in key international markets signal favorable conditions for LLY's global sales expansion.

Confidence: high

5. FRED (Federal Reserve Economic Data) — Interest Rates

Metric/field FEDFUNDS (Federal Funds Rate)

Cadence daily/monthly average

Why it matters Influences LLY's borrowing costs for its massive manufacturing build-out and M&A activities, as well as the broader economic environment affecting investment and consumer confidence.

Signal to watch Stable or declining rates could reduce financing costs and support investment.

Confidence: medium

Free Alt Data Watch

1. Google Trends — Search Interest

Metric/field Web Search Interest (relative volume) for 'Mounjaro', 'Zepbound', 'Foundayo', 'Retatrutide'

Cadence daily/weekly

Why it matters Reflects consumer awareness and interest in LLY's key growth drivers, especially important for direct-to-consumer marketing and market expansion.

Signal to watch Sustained or increasing search interest, particularly for newer launches like Foundayo and upcoming Retatrutide, indicates growing market demand.

Confidence: high

2. Reddit — Community Engagement

Metric/field Number of active users, posts/comments mentioning LLY products, sentiment analysis in r/diabetes and r/loseit

Cadence daily/weekly

Why it matters Provides qualitative insights into patient experiences, sentiment, side effects, and discussions around LLY's incretin therapies, influencing adoption and adherence.

Signal to watch Positive sentiment and increasing discussion volume around LLY products suggest strong patient engagement and satisfaction.

Confidence: medium

3. ClinicalTrials.gov (U.S. National Library of Medicine) — Study Records

Metric/field Status, Primary Completion Date, Results First Posted for LLY and competitor GLP-1 trials

Cadence event_driven

Why it matters Tracks progress and upcoming readouts for LLY's pipeline and competitive landscape, crucial for future revenue drivers and market positioning.

Signal to watch Timely completion and positive results postings for LLY's trials, or delays/negative results for competitors, are bullish.

Confidence: high

4. Centers for Medicare & Medicaid Services (CMS) — News Releases, Fact Sheets, Policy Documents

Metric/field Updates on Medicare Part D coverage for anti-obesity medications (AOMs) and GLP-1 Bridge Program guidance

Cadence event_driven

Why it matters Directly impacts access and reimbursement for LLY's obesity medicines in the crucial Medicare segment, which recently expanded coverage for 35% more Americans.

Signal to watch Favorable policy updates or expansions in coverage for AOMs under Medicare Part D are bullish for LLY's volume growth.

Confidence: high

5. U.S. Food and Drug Administration (FDA) — Drug Approvals and Databases

Metric/field New Drug Approvals (NDA/BLA), Supplemental Approvals (sNDA/sBLA), Labeling Changes for LLY and competitor products

Cadence event_driven

Why it matters Regulatory decisions are critical milestones for market entry, label expansion, and competitive positioning, directly impacting LLY's revenue potential.

Signal to watch Timely approvals and broad label indications for LLY's pipeline, or delays/restrictions for competitors, are bullish.

Confidence: high

Paid Alt Data Watch

1. IQVIA / Symphony Health — Prescription Data

Metric/field Total Prescriptions (TRx) and New Prescriptions (NBRx) for Mounjaro, Zepbound, Foundayo, and key competitor GLP-1s in the U.S.

Cadence weekly/monthly

Why it matters Provides direct, granular insight into market adoption, growth trajectory, and competitive share for LLY's most important products.

Signal to watch Sustained week-on-week growth in TRx and NBRx for LLY's products, especially Foundayo's inflection point, and market share gains against competitors.

Confidence: high

2. Komodo Health / Definitive Healthcare — De-identified Patient Claims Data

Metric/field Diagnosis rates for obesity/T2D, treatment initiation rates for GLP-1s, payer mix for LLY products, patient adherence/persistence rates

Cadence monthly/quarterly

Why it matters Offers deep insights into the patient journey, real-world utilization, payer dynamics, and adherence, which are critical for understanding long-term revenue streams and market penetration.

Signal to watch Increasing diagnosis and treatment initiation rates, favorable payer mix shifts (e.g., higher Medicare uptake), and strong adherence rates for LLY's products.

Confidence: high

3. Spherix Global Insights / Incisive Health — Physician Survey Data / Prescribing Behavior Analytics

Metric/field Physician awareness and perception of LLY products, prescribing intent for new LLY launches, competitive prescribing patterns, number of unique prescribers for Foundayo

Cadence quarterly

Why it matters Directly measures physician adoption and understanding of LLY's products, crucial for new launches and market share growth, especially for Foundayo's physician education efforts.

Signal to watch Increasing physician awareness, positive perception, and growing prescriber base for LLY's key products.

Confidence: high

4. Thinknum / SimilarWeb — Web Traffic Analytics

Metric/field Unique visitors to lillydirect.com, page views per visit, conversion rates, geographic traffic breakdown

Cadence weekly/monthly

Why it matters LillyDirect is a key component of LLY's direct-to-consumer strategy and expanding access. Monitoring its performance indicates the success of this channel.

Signal to watch Sustained growth in unique visitors and engagement, particularly in conversion metrics, signals successful direct patient outreach.

Confidence: medium

5. ImportGenius / Panjiva — Global Trade Data (Bill of Lading)

Metric/field Volume/value of active pharmaceutical ingredient (API) and raw material imports/exports by LLY (or its contract manufacturers) for key GLP-1 components

Cadence monthly

Why it matters Provides an early indicator of manufacturing output and supply chain health, crucial for LLY's ability to meet surging global demand and avoid supply constraints.

Signal to watch Consistent or increasing volumes of key API shipments indicate robust manufacturing and supply chain operations.

Confidence: low

Search Keywords Brand Product

Mounjaro
Zepbound
Foundayo
Retatrutide
Orforglipron
Ebglyss
Jaypirca
Inluriyo
Kisunla
Onswik
BPL-003
cleminorexton
amezosvatein
AJ1-11095
KLN-1010
brenipatide
mirikizumab
GLP-1 drugs
obesity treatment
diabetes medication
cardiometabolic health
immunology medicines
oncology drugs
neuroscience treatments
infectious disease prevention
mental health conditions
weight loss drugs
oral GLP-1s
injectable incretins
gene editing cardiovascular disease
treatment-resistant depression
vaccine development

Search Keywords Event Phrases

Lilly Q2 2026 Earnings
Foundayo U.S. launch
Foundayo international approvals
Retatrutide Phase 3 results
Orforglipron U.S. submission
Ebglyss FDA approval
Jaypirca EU approval
insulin efsitora alfa EU approval
AtaiBeckley acquisition
Curevo acquisition
LimmaTech Biologics acquisition
Vaccine Company acquisition
Medicare GLP-1 Bridge launch

Search Keywords Policy Regulatory

Medicare GLP-1 Bridge program
Medicare obesity coverage
drug reimbursement
FDA approval
EU approval
regulatory review
NRDL listing

What They Do (Plain English & Analogies): Eli Lilly and Company is a global pharmaceutical company that discovers, develops, and sells medicines for people worldwide. Think of them as highly specialized scientists and engineers who create advanced biological 'software' (drugs) to fix complex problems in the human body. Their main focus is on developing life-changing treatments for chronic conditions like diabetes and obesity, where their medicines help the body regulate its metabolism. They also work on 'security systems' (immunology drugs) to manage the body's immune responses, 'repair kits' (oncology drugs) to fight various cancers, and 'brain boosters' (neuroscience drugs) for conditions like Alzheimer's disease and mental health disorders. Recently, they've expanded into developing 'preventative maintenance' (vaccines) for infectious diseases and novel treatments for mental health conditions.
Very Brief History: Founded in 1876 by Colonel Eli Lilly in Indianapolis, Eli Lilly and Company became a global pharmaceutical leader by being the first to mass-produce penicillin and insulin. Over the last century, it evolved from a traditional chemical drug maker into a biotechnology powerhouse. Key milestones include the launch of Prozac in the 1980s, which revolutionized psychiatry, and the recent 2020s pivot to 'incretin' science (Mounjaro/Zepbound), which has made it one of the most valuable healthcare companies in the world by market capitalization.
"Street Stereotype": The 'Growth King' of Big Pharma. Lilly is generally perceived by investors more like a high-growth Silicon Valley tech stock than a traditional, slow-moving pharmaceutical company. Analysts view it as the gold standard for innovation in the obesity and Alzheimer's markets, often trading at a significant premium to its peers because of its massive 'moat' in manufacturing and its industry-leading pipeline.
Subsidiaries On Linked In*: Loxo Oncology at Lilly — LinkedIn: Loxo-Oncology-at-Lilly
Prevail Therapeutics — LinkedIn: prevail-therapeutics
Akouos — LinkedIn: akouos
Mablink Bioscience — LinkedIn: mablink-bioscience
Versanis Bio — LinkedIn: versanis-bio
Sigilon Therapeutics — LinkedIn: sigilon-therapeutics
Dice Therapeutics — LinkedIn: dice-therapeutics
Point Biopharma — LinkedIn: point-biopharma
Ventix Biosciences — Acquisition completed; LinkedIn: ventix-biosciences
Ajax Therapeutics — Acquisition announced April 2026; LinkedIn: ajax-therapeutics
Kelonia Therapeutics — Acquisition announced April 2026; LinkedIn: kelonia-therapeutics
Centessa Pharmaceuticals — Acquisition announced April 2026; LinkedIn: centessa-pharmaceuticals
Orna Therapeutics — Acquisition announced April 2026; LinkedIn: orna-therapeutics
Curevo — Acquisition announced; LinkedIn: curevo-vaccine
LimmaTech Biologics AG — Acquisition announced; LinkedIn: limmatech-biologics
The Vaccine Company — Acquisition announced; LinkedIn: vaccine-company-inc
AtaiBeckley Inc. — Acquisition announced; LinkedIn: ataibeckley
Customer Sectors & Example Clients: Lilly's primary customers are healthcare providers (doctors, hospitals) and patients. Their 'clients' in the business sense are the massive intermediaries that control drug distribution. These include: Pharmaceutical Wholesalers (e.g., McKesson, AmerisourceBergen, Cardinal Health); Pharmacy Benefit Managers/Payers (e.g., CVS Health/Caremark, UnitedHealth Group/OptumRx, Cigna/Express Scripts), with Lilly having secured commercial access across all 3 major PBMs for Foundayo in June. Government Entities (Medicare and Medicaid), notably through the Medicare GLP-1 Bridge program launched on July 1, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity. They also engage in Direct-to-Consumer sales via the LillyDirect platform.
New Customers / Segments They'Re Targeting: Lilly is actively targeting several new customer segments. A major focus is on expanding access for seniors in the U.S. through the Medicare GLP-1 Bridge program, which launched on July 1, 2026, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity at a low out-of-pocket price. This expands coverage by 35% in the United States. They are also targeting patients who prefer oral treatment options for obesity and type 2 diabetes with the global rollout of Foundayo (orforglipron), which is under regulatory review in over 40 countries. Internationally, Lilly is aiming to reach patients in resource-limited settings with a new commitment to address the growing burden of diabetes and obesity. Furthermore, through recent acquisitions, Lilly is expanding into new therapeutic areas, including infectious disease prevention and novel treatments for treatment-resistant depression and other mental health conditions, thereby targeting patients in these high-unmet-need areas.
Sales Geographies And Expansion Plans: Eli Lilly sells its products worldwide. In Q2 2026, U.S. revenue increased 33%, Europe revenue grew 55% in constant currency, Japan revenue grew 30% in constant currency, China revenue grew 93% in constant currency, and the rest of the world revenue grew 136% in constant currency, primarily driven by Mounjaro in Latin America and Asia. For Foundayo, Lilly launched for obesity in the UAE and recently received approval in Saudi Arabia for obesity and in Mexico for obesity and type 2 diabetes. Foundayo is under regulatory review in over 40 additional countries, with a global rollout expected in all major markets in 2027. Mounjaro is now reimbursed for both type 2 diabetes and obesity in France. Lilly is also replicating its LillyDirect offering outside the U.S. to ensure patients receive safe and authentic medicines.
How Key Themes May Help/Hurt: The 'GLP-1 Long '24: GLP1 Drug Producer' theme significantly benefits Lilly. The strong clinical evidence for GLP-1 drugs in treating obesity and comorbidities, as highlighted by retatrutide's profound weight loss and broad comorbidity benefits, drives increased adoption and expands Lilly's addressable market. The development and launch of oral GLP-1 formulations like Foundayo are expected to significantly increase patient compliance and market penetration, bringing in new patients who prefer oral options. Furthermore, the ongoing expansion of indications for GLP-1 drugs into areas like obstructive sleep apnea, knee osteoarthritis pain, and potentially irritable bowel syndrome, could further boost market growth and revenue streams. However, the theme also presents challenges. Increased competition from new entrants and alternative therapies, such as Novo Nordisk's oral GLP-1, could lead to market share erosion. Regulatory scrutiny concerning long-term side effects and pricing pressures, as seen with U.S. price declines for Zepbound and Mounjaro, could impact profitability. While Lilly is aggressively building manufacturing capacity, supply chain constraints, particularly for autoinjectors, could limit its ability to meet surging demand efficiently.

3 Main Long-Term Bull Details

Unparalleled Leadership and Pipeline in Cardiometabolic Health: Lilly's dominance with Mounjaro and Zepbound, combined with the 'unprecedented efficacy' of the triple-agonist Retatrutide and the market-expanding potential of Foundayo (oral GLP-1), positions the company for sustained leadership and significant market expansion across obesity, diabetes, and related comorbidities.
Strategic Diversification and Robust Pipeline beyond Incretins: Strong growth in Oncology (Jaypirca, selpercatinib, Inluriyo), Immunology (Ebglyss), and Neuroscience (Kisunla, AtaiBeckley acquisition, Centessa acquisition), coupled with strategic acquisitions in infectious disease and mental health, provides multiple future growth drivers and reduces reliance on a single therapeutic area.
Massive Manufacturing Moat and Expanded Patient Access: Aggressive manufacturing build-out, including new facilities in Lebanon, Indiana, and Limerick, Ireland, ensures robust supply to meet surging global demand. Expanded access through initiatives like the Medicare GLP-1 Bridge program and LillyDirect, despite pricing pressures, drives volume and market penetration.

3 Main Long-Term Bear Details

Significant Pricing Pressure and Potential Gross Margin Impact: Lilly's 'volume-over-price' strategy leads to ongoing U.S. price declines (3% in Q2, 9% excluding adjustments) due to expanded access agreements (Medicare, CVS). If volume growth cannot sufficiently offset these price erosions, or if new facility startup costs impact gross margins, profitability could be pressured.
Intensifying Competition and Internal Cannibalization Risk: Increasing competition in the GLP-1 market from rivals like Novo Nordisk (oral launches ex-U.S.) poses a threat. While Lilly aims for market expansion, the rapid succession of its own products (Zepbound, Foundayo, Retatrutide) creates a risk of internal cannibalization, potentially shortening peak revenue windows for individual brands.
Regulatory and Safety Scrutiny, and BLA Pathway Risks: Expansion into Medicare and Medicaid invites increased government scrutiny over long-term pricing and safety. The BLA pathway for Retatrutide, while strategically pursued, involves ongoing litigation and CMC development, introducing potential regulatory and execution risks that could delay market entry or impact initial launch.

Competitors And Differentiation: Lilly's primary competitors in the cardiometabolic space include Novo Nordisk, particularly with their GLP-1 products like Wegovy and Ozempic, and their oral semaglutide. Despite Novo scaling launches for its oral pill ex-U.S. and claiming strong initial share in the UAE, Lilly's combined incretin share held steady in the UAE, and its anti-obesity portfolio leads the U.S. market. Lilly differentiates itself through its strong portfolio of incretin medicines, including Mounjaro and Zepbound, which have extended its leadership position, and the upcoming retatrutide, which is a triple-acting GLP-1 with a 'pretty large lead over any competitors'. In other areas, Inluriyo is the U.S. leader in new prescriptions in the metastatic breast cancer oral SERD market, and Kisunla leads the U.S. anti-amyloid targeted therapy market. Lilly also faces competition from generic semaglutide in markets like India and Brazil, but Mounjaro continues to see TRx growth due to its strong differentiation and superiority data. Lilly's strategy also involves expanding the overall market with new oral options like Foundayo, which is showing an inflection point in U.S. uptake and is expected to expand the market for incretin therapy.
Recent Performance & What The Market'S Focused On: Eli Lilly reported robust Q2 2026 revenue growth of 48% compared to Q2 2025, driven by strong Mounjaro and Zepbound sales, which combined for $14.9 billion in revenue. The company significantly raised its full-year guidance to $85 billion to $87 billion. The successful launch of the Medicare GLP-1 Bridge program expanded access for obesity medicines, and the U.S. launch of Foundayo showed an inflection point in late July, with volumes almost doubling. Despite U.S. pricing pressure, with a 3% decline (9% excluding adjustments), volume growth fueled optimism. The market is focused on the sustained volume growth from the Medicare GLP-1 Bridge program, the continued acceleration of Foundayo's U.S. launch and its international rollout, and the successful navigation of the BLA regulatory pathway for retatrutide, with its U.S. submission expected in Q1 2027. Investors are also closely watching the U.S. realized price change to ensure volume gains effectively offset price erosion, and the progress of Lilly's aggressive manufacturing build-out to meet demand.

Revenue Segments And Estimated Mix: Total Revenue — Mix: 100%; Source: Q2 2026 earnings call; Trend: Grew 48% compared to Q2 2025, with full-year guidance raised to $85 billion and $87 billion
Key Products (Mounjaro, Zepbound, Ebglyss, Inluriyo, Jaypirca, Kisunla, etc.) — Mix: n/m (significant portion); Source: Q2 2026 earnings call; Trend: Increased by almost $6.8 billion; Oncology, Immunology, and Neuroscience medicines collectively grew 121%
Mounjaro and Zepbound (combined) — Mix: $14.9 billion; Source: Q2 2026 earnings call; Trend: Contributed $6.3 billion of growth compared to Q2 2025
U.S. Revenue — Mix: n/m; Source: Q2 2026 earnings call; Trend: Increased 33% in Q2, primarily driven by volume growth from Zepbound and Mounjaro
Europe Revenue — Mix: n/m; Source: Q2 2026 earnings call; Trend: Grew 55% in constant currency, driven by Mounjaro and a $250 million Jardiance milestone payment
Japan Revenue — Mix: n/m; Source: Q2 2026 earnings call; Trend: Grew 30% in constant currency, driven by Mounjaro and Kisunla
China Revenue — Mix: n/m; Source: Q2 2026 earnings call; Trend: Grew 93% in constant currency, driven by the uptake of Mounjaro
Rest of World Revenue — Mix: n/m; Source: Q2 2026 earnings call; Trend: Grew 136% in constant currency, driven by Mounjaro, primarily in Latin America and Asia
Product Brands: Basaglar
Humalog
Humalog Mix 75/25
Humalog U-100
Humalog U-200
Humalog Mix 50/50
insulin lispro
insulin lispro protamine
insulin lispro mix 75/25
Humulin
Humulin 70/30
Humulin N
Humulin R
Humulin U-500
Jardiance
Trajenta
Trulicity
Alimta
Cyramza
Erbitux
Retevmo
Tyvyt
Verzenio
Olumiant
Taltz
Cymbalta
Emgality
Zyprexa
Bamlanivimab
Etesevimab
Bebtelovimab
Cialis
Forteo
Inluriyo
Jaypirca
Mounjaro
Kisunla
Zepbound
Ebglyss
Foundayo
Onswik
retatrutide
orforglipron
amezosvatein
BPL-003
cleminorexton
AJ1-11095
KLN-1010
brenipatide
mirikizumab

Bull / Bear Details

As of 2026-08-06, Lilly remains the premier growth play in biopharma, driven by unparalleled leadership in cardiometabolic health. Robust Q2 performance, signif

Thesis

As of 2026-08-06, Lilly remains the premier growth play in biopharma, driven by unparalleled leadership in cardiometabolic health. Robust Q2 performance, significantly raised full-year guidance, and the successful Foundayo launch, coupled with groundbreaking Retatrutide data and expanded Medicare access, solidify its volume-driven market expansion. A deeply diversified pipeline across oncology, immunology, and neuroscience, bolstered by strategic acquisitions and massive manufacturing investments, underpins sustainable long-term growth despite pricing pressures.

Bull case

Lilly's metabolic franchise continues its exceptional growth, with Mounjaro and Zepbound combining for $14.9 billion in Q2 revenue. The Foundayo U.S. launch shows an inflection point, with international approvals expanding its global reach. Retatrutide's positive Phase 3 results demonstrate unprecedented weight loss and broad comorbidity benefits, positioning Lilly for multi-modality leadership and significant market expansion, further boosted by the Medicare GLP-1 Bridge program.
Beyond incretins, Lilly is rapidly diversifying its pipeline into high-value therapeutic areas. Recent positive Phase 3 data for pirtobrutinib in CLL and selpercatinib in NSCLC, coupled with strong Jaypirca growth, bolster oncology. Acquisitions like AtaiBeckley (neuroscience) and the infectious disease platform (Curevo, LimmaTech, Vaccine Company) demonstrate strategic expansion into new, high-unmet-need areas, ensuring sustainable long-term growth drivers.
Lilly's aggressive manufacturing build-out, including new facilities in Lebanon, Indiana, and Limerick, Ireland, ensures robust supply to meet surging global demand for its key products. This capacity, combined with the successful execution of its volume-over-price strategy and expanded patient access through the Medicare GLP-1 Bridge program and LillyDirect, underpins industry-leading revenue growth and market dominance.

Bear case

The strategic shift to 'volume-over-price' continues to introduce pricing pressures. Q2 2026 saw a U.S. price decline of 3% (9% excluding adjustments), and further reductions are expected due to expanded access agreements like CVS. If volume growth, despite strong performance, fails to sufficiently offset these realized price declines, or if gross margins are impacted by new facility startup costs, profitability could be pressured.
Intensifying competition in the GLP-1 market, including Novo's scaling oral launches ex-U.S. and its reported strong initial share in the UAE, poses a threat. While Foundayo is market-expansive, the rapid succession of Lilly's own products (Zepbound, Foundayo, Retatrutide) creates a risk of internal cannibalization, potentially shortening peak revenue windows for individual brands and leading to aggressive rebate wars.
Expansion into Medicare and Medicaid invites increased government scrutiny over long-term pricing and safety, with future access beyond the 2027 Medicare Bridge program subject to negotiation. The BLA pathway for Retatrutide, while strategically pursued, involves ongoing litigation and CMC development, introducing potential regulatory and execution risks that could delay market entry or impact initial launch.

Bull / Bear Case

Bear Case: Eli Lilly faces significant risks, primarily stemming from its premium valuation and increasing competitive pressures. The 'volume-over-price' strategy is already leading to U.S. price declines (9% ex-adjustments in Q2), which could accelerate with broader access agreements like CVS. Intensifying GLP-1 competition, notably Novo's strong oral launches ex-U.S., poses a threat, while Lilly's own rapid product succession (Zepbound, Foundayo, Retatrutide) risks internal cannibalization and margin erosion through rebate wars. Regulatory scrutiny over long-term pricing in Medicare/Medicaid and potential delays or complications with Retatrutide's BLA pathway introduce further execution and market entry risks, making the current valuation difficult to sustain.
Bull Case: Eli Lilly is poised for sustained, industry-leading growth, primarily driven by its dominant cardiometabolic franchise. Mounjaro and Zepbound delivered exceptional Q2 revenue, and the Foundayo U.S. launch is showing an inflection point, with global expansion underway. The groundbreaking Retatrutide, with unprecedented weight loss data, positions Lilly for multi-modality leadership. Expanded Medicare access significantly broadens the patient base. Beyond incretins, a diversified pipeline in oncology, immunology, and neuroscience, bolstered by strategic acquisitions, ensures future growth drivers. Aggressive manufacturing investments secure supply, supporting a volume-over-price strategy and solidifying market dominance. The company also raised its full-year revenue guidance to between $85 billion and $87 billion.
More Compelling & Why: Bear. Eli Lilly's current P/E ratio of approximately 60x is significantly higher than the pharmaceutical industry average of 20-25x, indicating a premium valuation that prices in substantial future growth. The intensifying competition in the GLP-1 market, coupled with Lilly's own rapid product succession (Zepbound, Foundayo, Retatrutide), creates a significant risk of internal cannibalization and aggressive rebate wars, which could pressure profitability and fail to justify the current premium valuation. Novo Nordisk's strong initial share in the UAE for its oral GLP-1 highlights this competitive threat. A sustained acceleration in Foundayo's U.S. and international launch trajectory that clearly demonstrates market expansion without significant cannibalization of existing Lilly incretins, alongside a clear resolution of the Retatrutide BLA pathway without delays, would justify the premium and flip my view to bullish.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Retatrutide U.S. Regulatory Submission (BLA Pathway)	Retatrutide, a triple-agonist, has shown 'unprecedented efficacy' and holds a significant lead over competitors. Its successful U.S. submission as a Biologics License Application (BLA) could establish it as a future market leader and reinforce Lilly's pipeline dominance.	Official announcement of the U.S. submission of retatrutide to the FDA in Q1 2027. Any updates on the ongoing litigation or conclusion with the FDA regarding the BLA pathway.	U.S. submission in Q1 2027 under the BLA pathway as planned is a bullish signal.	Lilly's Q4 2026 or Q1 2027 earnings calls. Company press releases. FDA announcements.	FDA website for drug application updates (though specific details might be limited). News and analyst reports covering FDA interactions for LLY.	EvaluatePharma: Regulatory status and timelines for retatrutide.
Incretin Manufacturing Capacity and Output	Lilly's ability to meet surging global demand for its incretin products (Mounjaro, Zepbound, Foundayo) is directly dependent on its manufacturing capacity. Continued expansion and successful commercial production are critical for sustained volume-driven growth.	Announcements regarding new manufacturing sites (e.g., Lebanon, Indiana; Limerick, Ireland) reaching full commercial production. Updates on the 'dose multiplier' target for FY 2026 (existing target 1.5x-1.8x).	New sites reaching 'commercial production' status as planned or ahead of schedule is a bullish signal. Exceeding the FY 2026 dose multiplier target is also bullish.	Lilly's Q3 2026 and Q4 2026 earnings calls. Company press releases. SEC filings (Form 10-Q, 10-K).	Local news reports on manufacturing facility progress in Indiana, Ireland, and Ohio. Industry news on pharmaceutical manufacturing capacity.	Supply chain intelligence platforms (e.g., Resilinc, Everstream Analytics): Monitoring for disruptions or expansions in Lilly's manufacturing network.
Medicare GLP-1 Bridge Program Volume Growth	The Medicare GLP-1 Bridge program, launched July 1, 2026, significantly expands access to obesity medicines for 20 million eligible Americans, increasing coverage by 35%. Its successful implementation and sustained volume growth are critical for Lilly's U.S. market penetration.	Monitor volume growth in the Medicare Part D segment for Lilly's obesity medicines (Zepbound, Foundayo) in Q3 2026 results. Observe the percentage of new patients coming from this program (currently estimated 60-70% new people) and the preference for injectables (around 80%).	Volume growth in the Medicare segment exceeding 25% quarter-over-quarter in Q3 2026 is a bullish signal. Continued strong preference for injectables (Zepbound) with robust new patient uptake is also bullish.	Lilly's Q3 2026 earnings call (expected October 29, 2026). CMS announcements or reports on GLP-1 utilization under the Bridge program.	News articles and healthcare industry reports on Medicare GLP-1 coverage uptake. Government data on Medicare Part D prescription trends (if publicly available with sufficient granularity).	Claims data providers (e.g., IQVIA, Symphony Health): Medicare Part D prescription volume for Zepbound and Foundayo.
Foundayo (Orforglipron) U.S. Launch Trajectory and International Rollout	Foundayo, Lilly's oral GLP-1, is crucial for expanding the obesity market by reaching patients who prefer pills. Its successful uptake and global availability are vital for Lilly's volume-driven growth strategy and competitive positioning against rivals.	Monitor U.S. total prescriptions (TRx) and new patient starts (NBRx) for Foundayo, particularly the sustained inflection point observed in late July. Watch for additional international approvals and launch cadence in major markets throughout 2026 and into 2027.	Sustained week-on-week growth in U.S. Foundayo TRx and NBRx, with new starts consistently around 1 out of 4 or higher, indicates bullish momentum. Additional international approvals in major markets in 2026 are also bullish.	Lilly's Q3 2026 earnings call (expected October 29, 2026) and subsequent earnings reports. Company press releases for international approvals. IQVIA prescription data.	Google Trends: 'Foundayo' search volume in the U.S. and key international markets (e.g., UAE, Saudi Arabia, Mexico). Social media sentiment analysis for 'Foundayo' on platforms like X or Reddit.	IQVIA: Foundayo NBRx and TRx data (U.S. and international). Symphony Health: Foundayo prescription data.
U.S. Realized Price Change for 2026	Lilly's 'volume-over-price' strategy involves strategic pricing concessions for broader market access. Monitoring the U.S. Realized Price Change is critical to assess if volume growth effectively offsets price erosion, impacting overall profitability.	Q3 2026 and Q4 2026 earnings reports for the reported U.S. Realized Price Change. Compare against the Q2 2026 decline of 3% (or 9% excluding adjustments) and any updated guidance for further erosion.	U.S. Realized Price Change reported as less negative than anticipated (e.g., less than the Q2 9% decline ex-adjustments) is a bullish signal.	Lilly's Q3 2026 and Q4 2026 earnings calls and financial statements (expected October 29, 2026, and late January/early February 2027, respectively).	Publicly available financial news and analyst reports summarizing Lilly's earnings.	Bloomberg Terminal/Refinitiv Eikon: Consensus estimates for price changes, historical reported price data.

Key Reported Metrics, Reratings Triggers & Results3 rows

Highlights Lilly's successful diversification beyond its core incretin franchise, demonstrating strong growth in other high-value therapeutic areas and validati

Upcoming print · 2026-10-29

Key reported metrics
Metric	Last period	Why it matters
Oncology, Immunology, and Neuroscience Revenue Growth	121%	Highlights Lilly's successful diversification beyond its core incretin franchise, demonstrating strong growth in other high-value therapeutic areas and validating its broader R&D and business development strategy.
U.S. Realized Price Change	-9%	Essential for assessing the financial impact of strategic pricing concessions for broad market access (Medicare, CVS). It indicates if volume gains are effectively offsetting price erosion and managing profitability amidst competitive pressures.
Total Revenue	$23.0 billion (48% y/y growth)	Directly reflects the success of Lilly's volume-over-price strategy and the market adoption of its key products, especially incretins. Investors will watch for continued top-line momentum and the impact of raised full-year guidance.

Last reported · 2026-08-05

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
US Realized Price Change	-7%	Achieving a US Realized Price Change better than the guided 'low-to-mid teens' would be a significant positive, indicating that Eli Lilly's 'volume-over-price' strategy is yielding stronger pricing outcomes than expected. This suggests strategic concessions for market access are not leading to as severe price erosion, strengthening the investment thesis by implying higher revenue and margin potential from its dominant GLP-1 franchise. Investors are watching for confirmation that volume growth can more than offset price declines, and a better-than-expected price metric would enhance this outlook.	The US Realized Price Change metric needs to be reported as less negative than the company's guided 'low-to-mid teens' price erosion for 2026. Specifically, a value of -9% or better (i.e., less negative than -9%) would signal that pricing headwinds are being managed more effectively than anticipated, outperforming the expected acceleration from the current -7%.	Achieving a US Realized Price Change better than the guided 'low-to-mid teens' would be a significant positive, indicating that Eli Lilly's 'volume-over-price' strategy is yielding stronger pricing outcomes than expected. This suggests strategic concessions for market access are not leading to as severe price erosion, strengthening the investment thesis by implying higher revenue and margin potential from its dominant GLP-1 franchise. Investors are watching for confirmation that volume growth can more than offset price declines, and a better-than-expected price metric would enhance this outlook.	2026-08-05	-9%	Yes	U.S. price declined by 3%, but excluding adjustments for rebates and discounts, the decline was 9%. This met the rerating trigger of -9% or better. Management indicated that while price is expected to go down due to increased access (e.g., CVS), this will be offset by volume growth.
Total Revenue	43%	Hitting this threshold validates Lilly's 'volume-over-price' strategy, demonstrating that robust demand for GLP-1 drugs and the successful launch of Foundayo are effectively offsetting pricing pressures. It reinforces the investment thesis of Lilly as a dominant growth play in biopharma, expanding its market share and pipeline, thereby justifying its premium valuation and driving further investor confidence.	Eli Lilly's Total Revenue needs to report Q2 2026 year-over-year growth of at least 40%, significantly exceeding analyst consensus estimates of approximately $20.5 billion to $20.66 billion. Additionally, the company must reaffirm or, ideally, further raise its recently increased full-year 2026 revenue guidance of $82 billion to $85 billion.	Hitting this threshold validates Lilly's 'volume-over-price' strategy, demonstrating that robust demand for GLP-1 drugs and the successful launch of Foundayo are effectively offsetting pricing pressures. It reinforces the investment thesis of Lilly as a dominant growth play in biopharma, expanding its market share and pipeline, thereby justifying its premium valuation and driving further investor confidence.	2026-08-05	$23.0 billion (48% y/y growth)	Yes	Eli Lilly reported Q2 2026 revenue of $23.0 billion, representing a 48% year-over-year increase. This significantly exceeded analyst consensus estimates of approximately $20.5 billion to $20.66 billion. The company also raised its full-year 2026 revenue guidance to between $85 billion and $87 billion, up from the previous range of $82 billion to $85 billion.
FDA Approval and US Launch of Orforglipron (Oral GLP-1)	N/A	Hitting this threshold validates Lilly's market expansion thesis for oral GLP-1s, demonstrating strong patient uptake and competitive positioning against rival oral therapies. It signals that Foundayo is effectively reaching new patients and expanding the overall obesity market, reinforcing Lilly's dominant growth narrative and justifying its premium valuation.	FDA approval for Orforglipron (Foundayo) for obesity was achieved on April 1, 2026. For a higher rerating, the US launch needs to demonstrate a significant acceleration in initial prescription (NBRx) ramp, specifically exceeding 50,000 weekly prescriptions within the first 12 weeks post-launch. This would indicate a stronger competitive trajectory against peer oral GLP-1 launches and a clear path towards meeting or exceeding analyst 2026 sales estimates.	Hitting this threshold validates Lilly's market expansion thesis for oral GLP-1s, demonstrating strong patient uptake and competitive positioning against rival oral therapies. It signals that Foundayo is effectively reaching new patients and expanding the overall obesity market, reinforcing Lilly's dominant growth narrative and justifying its premium valuation.	2026-08-05	Q2 sales of $98 million; 'almost doubling the volume' in late July; 'new starts coming in nearly around 1 out of 4'	No	While Foundayo generated $98 million in sales for Q2 and management noted an inflection point in late July with volumes almost doubling, specific weekly prescription (NBRx) data to confirm exceeding 50,000 prescriptions within the first 12 weeks post-launch was not provided in the earnings report. Management acknowledged the U.S. launch curve was 'somewhat slower than anticipated' but is gaining momentum with increased access and consumer awareness.

Key Questions

Can Lilly's 'volume-over-price' strategy continue to drive robust revenue growth in Q3 2026, particularly as the Medicare GLP-1 Bridge program ramps up and Foun

Can Lilly's 'volume-over-price' strategy continue to drive robust revenue growth in Q3 2026, particularly as the Medicare GLP-1 Bridge program ramps up and Foundayo's U.S. launch inflects, effectively offsetting the ongoing U.S. price declines?

Question 2: Can Foundayo sustain its recent U.S. inflection point and achieve significant market expansion, both domestically with full DTC promotion and internationally against intensifying competition from Novo Nordisk's oral GLP-1, without substantial cannibalization of Lilly's existing injectable incretins?
Question 3: Will Lilly successfully navigate the BLA regulatory pathway for retatrutide, ensuring its U.S. submission in Q1 2027, and will upcoming Phase 3 readouts for additional indications (e.g., obstructive sleep apnea, chronic lower back pain) further solidify its superior efficacy and tolerability profile to secure its future market leadership?

Earnings Transcript Summary2 rows

2026-08-05 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Sustaining robust revenue growth, particularly from Key Products (Mounjaro, Zepbound) and expanding their global reach: Management highlighted robust revenue growth across all Key Products and major geographies, leading to raised full-year guidance. They emphasized continued strong performance of Mounjaro and Zepbound globally. 2. Advancing and expanding the pipeline across therapeutic areas through internal R&D and strategic business development: Management detailed significant pipeline progress in Cardiometabolic Health (retatrutide, orforglipron), Neuroscience (AtaiBeckley acquisition, Centessa acquisition), Oncology (Jaypirca, selpercatinib, Ajax, Kelonia acquisitions), and Immunology (Ebglyss, brenipatide). They also highlighted acquisitions in infectious disease prevention and mental health. 3. Expanding patient access and affordability for obesity treatments, while continuing manufacturing scale-up: Management discussed the successful launch of the Medicare GLP-1 Bridge program, expanding access for 35% more Americans. They also focused on the global rollout of Foundayo, with approvals in UAE, Saudi Arabia, and Mexico, and plans for major markets in 2027, supported by ongoing manufacturing build-out.	Call Takeaway & ToneThe overall tone of the call was exceptionally positive and confident. Management delivered strong Q2 2026 financial results, significantly exceeding expectations and raising full-year guidance. The key takeaway was Lilly's continued dominance and expansion in the cardiometabolic health market, driven by Mounjaro and Zepbound, and the promising early momentum of Foundayo, both in the U.S. and internationally. The company is actively pursuing a strategy of volume-driven growth, expanding patient access through initiatives like the Medicare GLP-1 Bridge program, and strategically diversifying its pipeline through robust internal R&D and targeted acquisitions in emerging therapeutic areas like infectious disease and mental health. Management expressed strong confidence in their ability to deliver industry-leading growth and maximize the potential of their innovative pipeline.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue (Q1 2026): 56%. Key Products (Immunology, Oncology, and Neuroscience therapeutic areas combined, Q1 2026): 160%. U.S. Revenue (Q1 2026): 43%. Europe Revenue (Q1 2026): 37% in constant currency. Mounjaro (Worldwide, Q1 2026): 125%. Zepbound (Q1 2026): 80%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Foundayo launch trajectory in the U.S. and competitive dynamics ex-U.S.: Analysts questioned the slower U.S. launch and competition from Novo's oral pill internationally. Management responded that they are making meaningful progress by educating physicians, securing access (CVS, Medicare Bridge), and launching DTC campaigns, noting an inflection point in late July with volumes almost doubling. For ex-U.S., they reported a strong start in UAE, expanding the market with naive patients, and Lilly's combined incretin share holding steady despite competition, with strong supply for upcoming launches. 2. Retatrutide's regulatory pathway (BLA classification): Analysts inquired about the BLA pathway for retatrutide and its implications. Management affirmed their position that retatrutide is a biologic application, citing amino acid count and analogy to a protein. They mentioned ongoing litigation but expressed hope for a conclusion with the FDA to support a BLA, with submission planned by Q1 2027, emphasizing the drug's unprecedented efficacy. 3. Medicare obesity rollout learnings and initial ramp: Analysts asked for more details on the Medicare GLP-1 Bridge program's initial impact and trends between orals and injectables. Management expressed excitement about expanding access for seniors and noted a significant inflection point in the last few weeks. They observed a strong preference for injectables (around 80%) among new patients, with 60-70% being individuals who previously lacked access.	Revenue SegmentsTotal Revenue: 48% growth compared to Q2 2025. Key Products: increased by almost $6.8 billion. Oncology, Immunology, and Neuroscience medicines (collectively within Key Products): 121% growth compared to Q2 2025. U.S. revenue: 33% increase. Europe revenue: 55% growth in constant currency. Japan revenue: 30% growth in constant currency. China revenue: 93% growth in constant currency. Rest of world revenue: 136% growth in constant currency. Immunology (Ebglyss): worldwide sales more than doubled (implying >100% growth) compared to Q2 2025. Oncology (Jaypirca): worldwide sales increased 56% compared to Q2 2025. Cardiometabolic Health (Mounjaro and Zepbound): combined for $14.9 billion of revenue, contributing $6.3 billion of growth compared to Q2 2025.

2026-02-04 · 2025Q4 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Manufacturing Capacity: Executing a $55 billion build-out to sustain 1.8x annual increases in incretin doses and support global demand. 2. Oral GLP-1 Launch: Preparing for the 2026 US launch of Orforglipron, which management believes will expand the market by reaching patients who prefer orals over injectables. 3. Pipeline Diversification: Reinvesting obesity profits into 'non-obesity' areas, specifically Phase 3 programs in Immunology (Taltz/Zepbound combos) and Oncology (Pirtobrutinib and Imlunestrant).	Call Takeaway & ToneTone: Exceptionally Bullish and Aggressive. Takeaway: Lilly is entering a 'volume-over-price' phase where they are willing to accept lower realized prices in exchange for dominant market share and broad access (Medicare/Medicaid). The company is successfully leveraging its obesity franchise to fund a massive R&D expansion, having achieved nearly all clinical milestones in 2025.	Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: +42%; Key Products: +85%; US Revenue: +46%; Omvo: +50%; Jayperca: +28%; Verzenio: +32%.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Orforglipron Market Dynamics: Analysts questioned if the oral GLP-1 would cannibalize Zepbound. Management responded that early competitor data suggests orals are 'market expansive,' bringing in new patients who were previously on the sidelines. 2. 2026 Pricing Headwinds: Analysts pressed on the guidance for 'low to mid-teens' price declines. Management explained this is a strategic trade-off for massive volume gains through Medicare access and China's NRDL listing. 3. International Growth Sustainability: Analysts asked if the OUS Mounjaro surge was a one-time event. Management clarified that Q4 2025 is the new baseline for 2026, with 75% of OUS revenue coming from the self-pay chronic weight market.	Revenue SegmentsTotal Revenue: +43%; Key Products (Mounjaro, Zepbound, etc.): +91%; US Revenue: +43%; OUS Revenue: Double-digit growth in Europe/Japan/China and +100% in Rest of World; Omvo: +55%; Jayperca: +30%; Verzenio: +3%; Kisanlo: $109M (revenue, not y/y growth).

Transcript Tidbits4 rows

2026-08-05

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketLilly is significantly expanding its eligible market through several initiatives and product advancements. The Medicare GLP-1 Bridge program launched on July 1, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity at a low out-of-pocket price of $50 per month, which expands coverage by 35% in the United States. Foundayo has been launched for obesity in the UAE, and received approval in Saudi Arabia for obesity and in Mexico for obesity and type 2 diabetes, with regulatory review ongoing in over 40 additional countries. The company anticipates a global rollout of Foundayo in all major markets in 2027. Additionally, the U.S. FDA approved Ebglyss for maintenance dosing once every 8 weeks in atopic dermatitis, and the EU approved Jaypirca in CLL across all lines of therapy. Retatrutide's clinical data package now supports global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain. Lilly also completed the U.S. submission of orforglipron for type 2 diabetes. The company expanded its pipeline through business development, acquiring Curevo, LimmaTech Biologics, and the Vaccine Company to build a platform for preventing infectious diseases, and AtaiBeckley for novel treatments for treatment-resistant depression and other mental health conditions. Lilly is also developing a new commitment to address the growing burden of diabetes and obesity in resource-limited settings worldwide. The company is expanding its LillyDirect offering to make it easier for people to access care, and has launched versions of LillyDirect outside the U.S.	About CompetitionLilly's incretin portfolio has extended its leadership position, with the company's anti-obesity portfolio leading the U.S. incretin analogs obesity market, accounting for approximately 6 out of 10 total prescriptions and 7 out of 10 injectable prescriptions in Q2. In the U.S. type 2 diabetes incretin analogs market, Lilly's portfolio also leads with more than 6 out of 10 prescriptions for an incretin being a Lilly medicine. Globally, Lilly is the market leader in the international incretin analogs market, strengthening its position to approximately 55% share. Inluriyo has become the U.S. leader in new prescriptions in the metastatic breast cancer oral SERD market with over 50% share after only two full quarters. Kisunla expanded its leadership position in the U.S. anti-amyloid targeted therapy market. While Novo is scaling launches for its oral pill in several ex-U.S. countries and claimed 50% share within three weeks of launch in the UAE, Lilly's combined incretin share held steady in the UAE. Retatrutide is noted to have a 'pretty large lead over any competitors with a triple-acting medicine'. Despite the launch of generic semaglutide in India and Brazil, Mounjaro continues to see TRx growth, attributed to its strong differentiation and superiority data, and generic companies are experiencing significant supply constraints.	About The Broader IndustryThe broader industry is seeing a significant opportunity in the treatment of obesity, with current utilization or treatment in the U.S. and globally still in the mid-single digits. There is a growing trend towards consumer activation in the obesity market, particularly outside the U.S. where it is still mainly out-of-pocket. The early uptake of oral GLP-1s is encouraging, as it is expanding the market of people taking incretin therapy. Injectable incretins remain an important growth driver, accounting for three out of four new patient starts. Diagnostic testing momentum for Alzheimer's disease continues to build, with P-tau217 blood tests more than doubling compared to Q2 2025, leading to more diagnoses and treatment access. The global growth of antimicrobial resistance highlights the important role vaccines to prevent bacterial infection could play. Self-pay continues to be a significant segment within the obesity market, accounting for approximately 45% of total Zepbound prescriptions in Q2 and 55% of new prescriptions.	Where Things Are HeadedLilly has raised its full-year annual revenue guidance to between $85 billion and $87 billion, and expects non-GAAP performance margin to be between 49% and 50.5%, with non-GAAP earnings per share of $35.50 to $36.50. The company expects regulatory action for Foundayo for type 2 diabetes later this year, with additional international approvals anticipated this year and a global rollout in all major markets in 2027. Foundayo will also have readouts from many additional clinical trials, starting with obstructive sleep apnea later this year. Lilly plans to submit retatrutide in the U.S. in Q1 2027 under the BLA pathway. European approval for insulin efsitora alfa is expected in the coming months. The company intends to remain active in business development, focusing on areas of significant unmet need and exciting early science. The readout of EMBER-4 for Inluriyo in the adjuvant setting is expected next year, and a chronic lower back pain study with retatrutide will also read out next year. Lilly envisions combining Inluriyo with Tersolisib (PI3 kinase inhibitor) and existing endocrine therapies, including Verzenio, for an all-oral combination in breast cancer. While Zepbound's price is expected to decrease due to CVS access, this will be offset by volume growth. Seasonality effects in Europe (Q3 vacations) and U.S. type 2 diabetes (Q4) are factored into the guidance.	Updates On ThemeGLP1	Broader Themes EmergingThe 'Consumerization of Pharma' continues to emerge, with Lilly expanding direct-to-consumer marketing for Foundayo and replicating LillyDirect practices outside the U.S. to reach patients directly. The theme of 'Incretins as a Platform' is reinforced by the expansion of incretin biology into new settings, such as Phase 2 trials of brenipatide for irritable bowel syndrome. Additionally, the acquisitions of Curevo, LimmaTech Biologics, and the Vaccine Company highlight an emerging focus on 'Vaccines for Infectious Diseases' to prevent acute disease and long-term complications, including addressing antimicrobial resistance. The acquisition of AtaiBeckley also points to an emerging theme of 'Novel Treatments for Mental Health Conditions', specifically for treatment-resistant depression.	Bullish-Leaning Quotes (Short)Q2 continued Lilly's strong momentum. We delivered robust revenue growth across all Key Products and major geographies. Revenue grew 48% compared to Q2 of 2025. We raised our full-year annual guidance. Lilly's portfolio of medicines extended its leadership position. Early uptake in the UAE has been encouraging. Positive topline results in 3 Phase 3 retatrutide trials in obesity. 35% more people now have coverage for our obesity medicines in the United States. Mounjaro and Zepbound had another strong quarter, combining for $14.9 billion of revenue. Lilly is the global market leader, and we strengthened that position. Foundayo has the potential to help millions of people. We now expect full-year revenue to be between $85 billion and $87 billion. We are confident in our ability to deliver another year of industry-leading growth. Retatrutide delivered a magnitude of weight loss not previously seen. Orforglipron delivered superior glycemic control and weight reduction against oral semaglutide. This study has the potential to establish a new standard of care [CLL]. Selpercatinib reduced the risk of disease recurrence or death by 83%. We have the strongest pipeline we've ever had.	Bearish-Leaning Quotes (Short)U.S. price declined by 3%, driven by Zepbound and Mounjaro. Excluding these adjustments, U.S. price declined by 9%. Foundayo launch. In the U.S., the launch curve has been somewhat slower than anticipated. Novo... got 50% share within 3 weeks of launch [in UAE]. Price will actually go down for sure because of this. Seasonality in Europe in Q3 with all the vacation holidays taking place. We have some seasonality in type 2 diabetes in the U.S. in the fourth quarter.	HiringLilly mentioned welcoming the AtaiBeckley team to Lilly and progressing clinical development alongside the teams from Ajax and Kelonia, indicating workforce expansion through acquisitions and integration of new teams.

2026-02-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketLilly is significantly expanding its addressable market through a US government agreement to provide Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is also targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, and psoriatic arthritis. The direct-to-patient platform reached 1 million users, with Zepbound vials making up one-third of new patient starts.	About CompetitionZepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of the US type 2 diabetes incretin market. In neuroscience, Kisanlo has become the US market leader in amyloid-targeting therapies with over 50% share. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations.	About The Broader IndustryThe industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing $55 billion since 2020. Additionally, the integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation lab with NVIDIA and the use of supercomputing to shorten discovery timelines.	Where Things Are HeadedLilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth. Key milestones include the US launch of Orforglipron for weight management in 2026, six Phase 3 readouts for the triple-agonist Retatrutide, and the expansion of incretins into psychiatry (alcohol use disorder, MDD). The company expects industry-leading volume growth to be partially offset by low-to-mid-teen price erosion due to government access agreements.	Updates On ThemeLilly	Broader Themes EmergingThe 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders.	Bullish-Leaning Quotes (Short)"2025 full-year revenue grew 45% compared to 2024."; "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions."; "Retatrutide... lost an average of 29% of their body weight."; "Kisanlo recently became the US market leader in the amyloid-targeting therapy space."	Bearish-Leaning Quotes (Short)"Price is expected to be a drag on growth in the low to mid-teens."; "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage."; "Gross margin will be... offset by price and new facilities coming online."; "Overall market penetration has reached a plateau [for Verzenio]."

2026-02-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketLilly is significantly expanding its addressable market through a US government agreement to provide Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is also targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, and psoriatic arthritis. The direct-to-patient platform reached 1 million users, with Zepbound vials making up one-third of new patient starts.	About CompetitionZepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of the US type 2 diabetes incretin market. In neuroscience, Kisanlo has become the US market leader in amyloid-targeting therapies with over 50% share. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations.	About The Broader IndustryThe industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing $55 billion since 2020. Additionally, the integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation lab with NVIDIA and the use of supercomputing to shorten discovery timelines.	Where Things Are HeadedLilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth. Key milestones include the US launch of Orforglipron for weight management in 2026, six Phase 3 readouts for the triple-agonist Retatrutide, and the expansion of incretins into psychiatry (alcohol use disorder, MDD). The company expects industry-leading volume growth to be partially offset by low-to-mid-teen price erosion due to government access agreements.	Updates On ThemeLilly	Broader Themes EmergingThe 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders.	Bullish-Leaning Quotes (Short)"2025 full-year revenue grew 45% compared to 2024."; "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions."; "Retatrutide... lost an average of 29% of their body weight."; "Kisanlo recently became the US market leader in the amyloid-targeting therapy space."	Bearish-Leaning Quotes (Short)"Price is expected to be a drag on growth in the low to mid-teens."; "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage."; "Gross margin will be... offset by price and new facilities coming online."; "Overall market penetration has reached a plateau [for Verzenio]."

2026-02-04

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketLilly is expanding its addressable market through a US government agreement for Medicare and Medicaid access to obesity medicines by July 1, 2026, with a $50 out-of-pocket cap. The company is targeting 'sidelined' patients with the upcoming launch of Orforglipron (oral GLP-1) and expanding into new indications including sleep apnea, osteoarthritis, psoriatic arthritis, substance use disorders, bipolar disorder, and major depressive disorder. The direct-to-patient platform reached 1 million users in 2025, with Zepbound self-pay vials making up one-third of new patient starts. Mounjaro has launched in new international markets and is now the incretin share of market leader outside the US. Jayperca received an expanded US indication for people previously treated with a covalent BTK inhibitor, and pirtobrutinib received full FDA approval with an expanded indication for relapsed/refractory CLL, SLL.	About CompetitionZepbound maintains a dominant 70% share of new prescriptions in the branded obesity market, while Mounjaro holds over 55% of new prescriptions in the US type two diabetes incretin market and is now the incretin share of market leader outside the US. Kisanlo became the US market leader in amyloid-targeting therapy with over 50% share of total prescriptions. Management noted that competitor oral launches (oral Wegovy) appear to be market-expansive rather than cannibalistic, validating the demand for oral formulations. Pirtobrutinib showed compelling risk reduction in CLL/SLL compared to bendamustine plus rituximab and non-inferiority to ibrutinib. Oloralintide demonstrated excellent tolerability, potentially benefiting patients who cannot tolerate incretins.	About The Broader IndustryThe industry is shifting toward 'consumer centricity' and direct-to-patient delivery models to reduce friction. There is a massive structural build-out in manufacturing, with Lilly committing over $55 billion since 2020. The integration of AI in drug discovery is accelerating, evidenced by Lilly's new co-innovation AI lab with NVIDIA and the use of supercomputing. There is a growing body of evidence supporting the recognition of obesity as a chronic disease.	Where Things Are HeadedLilly issued 2026 revenue guidance of $80 billion to $83 billion, representing 25% growth, driven by industry-leading volume growth partially offset by low to mid-teens price erosion. The US launch of Orforglipron for chronic weight management is expected in 2026, with international launches in 2027. New Medicare access to obesity medicines is anticipated no later than July 1, 2026. Six additional Phase 3 trials for retreutide are expected to read out in 2026, with submissions for overweight/obesity, obstructive sleep apnea, and knee osteoarthritis planned for 2026. R&D expenses are expected to scale up in 2026 with 36 active Phase III programs and more new programs, alongside increased marketing, selling, and administrative expenses to support new launches. EPS is projected between $33.50 and $35.	Updates On ThemeGLP1	Broader Themes EmergingThe 'Consumerization of Pharma' is emerging as a major theme, with subscription-like models and direct-to-consumer digital platforms (LillyDirect) bypassing traditional pharmacy frictions. Another emerging theme is 'Incretins as a Platform,' where metabolic drugs are being tested as foundational treatments for immunology, substance abuse, and psychiatric disorders.	Bullish-Leaning Quotes (Short)"2025 full-year revenue grew 45% compared to 2024." "Zepbound continues to be the market leader... with nearly 70% share of new prescriptions." "Retreutide... lost an average of 29% of their body weight at 68 weeks." "Kisanlo recently became the US market leader in the amyloid-targeting therapy space." "We exceeded our goal to produce 1.8 times the number of incretin doses in 2025 compared to 2024."	Bearish-Leaning Quotes (Short)"Price is expected to be a drag on growth in the low to mid-teens." "Anticipate a reduction in Medicaid access in 2026 due to key states like California removing obesity coverage." "Gross margin will be... offset by price and new facilities coming online." "Overall market penetration has reached a plateau [for Verzenio]."	HiringLilly strengthened its leadership team with the addition of two new executives, Carole Ho and Anne White.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-08-05	Eli Lilly reported robust Q2 2026 revenue growth of 48% and significantly raised full-year guidance to $85-$87 billion, driven by strong Mounjaro and Zepbound sales and promising early Foundayo uptake. The successful Medicare GLP-1 Bridge program expanded access. Despite U.S. pricing pressure, volume growth fueled optimism. The stock surged 6.84% (outperforming SPY), indicating strong market confidence in Lilly's growth trajectory and pipeline.	Earnings Transcript	Positive		+6.84% (vs SPY: +7.20%)

Upcoming Events3 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
LLY_48d9403d	later this year	2026-10-01	2026-12-31	Readout of Foundayo Phase 3 trial in obstructive sleep apnea.	Positive results from this trial could lead to a new, high-value indication for Foundayo, further expanding its utility and market potential beyond its current metabolic indications.	Ticker	2026-08-05	earnings_transcript
LLY_696cb569	later this year	2026-10-01	2026-12-31	U.S. regulatory action (approval/decision) for Foundayo in type 2 diabetes.	This regulatory decision would significantly expand Foundayo's addressable market in the U.S. to include type 2 diabetes, a large and established indication, driving substantial revenue growth.	Ticker	2026-08-05	earnings_transcript
LLY_cf82d1b5	a few markets late in 2026	2026-10-01	2026-12-31	Launch of Orforglipron in a few international markets (e.g., UAE).	This marks the beginning of the international rollout for oral Orforglipron, contributing to global revenue growth and market penetration.	Ticker	2026-02-04	earnings_transcript

Prior Earnings Metrics HistoryTable

Prior earnings scorecards